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Abstract
The distribution of copper in Sprague-Dawley rats following a three month oral
administration of 0,10 or 50mg/kg copper aspirinate has been investigated. Metal
content was determined by ICP-AES in blood, brain, kidney, liver, lung, spleen, and
dejection. The results show that treatment with copper aspirinate did not cause
accumulation of copper in rats and excess ingested copper was excreted through
feces.
1. Introduction
Since the first report by Prof. J.R.J. Sorenson that copper complexes of many
ligands had anti-inflammatory activity[1],copper aspirinate[Cu(ASA)],the copper
complex of aspirin, has been found to be much more effective as an an-
ti-thrombotic agent [] as well as an anti-inflammatory agentrZ].ln addition,it has
antiulcer activity TM which distinguishes it from aspirin. It is, therefore, suggested
that copper aspirinate should be clinically used in treating thrombotic and arthritic
diseases [][]. However doctors are still concerned about the relative large amount
of copper that may be ingested. Excess copper intake may be harmful to mankind
although it is an essential metalloelement. Prof. J.R.J. Sorenson has studied the
preliminary toxicity of copper aspirinate Is]. As an expansion of this toxicity study
and part of the pharmacological evaluation,the present investigation is made to
see whether accumulation of copper will occur in rats following a three month
oral treatment with 0,10 or 50mg/kg copper aspirinat.
2. Materials and Methods
Copper aspirinate was prepared and purified by the method previosly described [].
Elemental analysis, IR, UV and MS-FAB* corresponded to the known chemical
structure [e] The complex was suspended in 1.4% polyvinyl alcohol and 5%
propylene glycol immediately prior to intragastric administration.
Three groups of twenty Sprague-Dawley rats of either sex were given orally the
vehicle, lO,or 50 mg/kg copper aspirinate six days a week for three months. Treat-
ment ceased at the end of the third month. The remaining animals were continued
without treatment for an additional month. These rats were massed weekly during
treatment and doses of copper aspirinate changed weekly according to body mass
in order to maintain the original doses of 10 or 50 mg/kg.
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At the end of each month,five rats were killed by cervical dislocation.Blood sam-
ples were collected immediately by cardiac puncture. Samples of liver,kidney,spleen
and brain were dissected and massed. Feces were also collected at the end of the
third month. All samples were frozen and stored prior to metal content analysis.
After thawing,samples were digested in concentrated nitric acid at 90C ,and then
perchloric acid was added,followed by a gentle heating. The resulting solutions
were clear. After diluted,they were analyzed for copper content using Inductively
Coupled Argon Atomic Emission Spectrophotometry (ICP-AES) at 324.7nm.
Table 1. Blood copper concentration (x+S.E.M,n=5) for non-treated and
copper aspirinate-treated rats at the end of each month
Group Dose Cu(/g/g wet mass)
30 days 60 days 90 days 120 days
Control
Cu2(ASA)4 0 mg/kg
50 mg/kg
1.05 + 0.20 1.10 + 0.10 1.30 + 0.20 1.24 + 0.10
1.12 + 0.30 1.14+ 0.10 1.16 + 0.30 1.16 + 0.20
1.20 + 0.20 1.31 + 0.20 1.26 + 0.20 1.18 + 0.20
Table 2. Liver copper concentration (x_+ S.E.M, n=5) for non-treated and copper
aspirinate-treated rats at the end of each month
Group Dose Cu(/g/g wet mass)
30 days 60 days 90 days 120 days
Control
Cu2(ASA)4 0 mg/kg
50 mg/k g
3.10 + 0.20 4.10 + 0.50 4.40 + 0.50 4.30 + 0.50
3.55 + 0.40 4.20 + 0.40 4.30 + 0.50 3.80 + 0.30
3.30 + 0.50 4.30 + 0.40 4.20 + 0.60 4.10 -+ 0.60
3. Results and Discussion
Tissue distribution of copper are shown in Table to 5. There were no significant
differences in copper concentration among non-treated, 10 mg/kg and 50 mg/kg
copper aspirinate-treated groups. This means chronic oral treatment with 10 or
50mg/kg copper aspirinate did not cause accumulation of copper in blood,liver,kid-
ney,brain or spleen. The 50 mg/kg dose of copper aspirinate represents a daily in-
take of 7.5 mg copper per kg,much larger than needed for normal metabolism,but
did not cause accumulation. These results are consistent with the understanding
that normal animals can excrete ingested copper in excess of homeostatic
requirements.
Table 3. Kidney copper concentration (x + S.E.M,n 5) for non- treated and copper
aspirinate-treated rats at the end of each month
Group Dose Cu(/g/g wet mass)
30 days 60 days 90 days 120 days
Control 5.60 + 1.30 5.70 + 1.30 5.90 + 1.20 6.20 + 1.20
Cu(ASA)4 10 mg/kg 4.80 + 1.10 5.50 + 1.00 5.70 + 1.40 6.50 + 1.30
50 mg/kg 5.40 + 0.90 6.40 + 2.10 6.10 + 1.50 5.80 + 1.10
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Table 4. Spleen copper concentration (x S.E.M, n 5) for non
aspirinate-treated rats at the end of each month
treated and copper
Group Dose Cu(lg/g wet mass)
30 days 60 days 90 days 120 days
Control 1.10 + 0.80 1.30 _+_ 0.30 1.40 0.20 1.30 0.20
Cu2(ASA)4 10 mg/kg 1.40+_0.30 0.90: 0.10 1.10:# 0.30 1.40 0.10
50 mg/kg 1.50 +- 0.50 1.40+_ 0.30 1.60 _+_ 0.40 1.50 r 0.30
Data presented in Table 6 show that copper concentration in feces of treated
animals, particularly with a dose of 50 mg/kg, was much higher than that of
non-treated animals,which suggests that excess copper intake was excreted via
feces. Bile may serve as the major excretory vehicle.
Table 5. Brain copper concentration (x+ S.E.M, n--5) for non-treated and copper
aspirinate-treated rats at the end of each month
Group Dose Cu(/g/g wet mass)
30 days 60 days 90 days 120 days
Control 2.20 + 0.20 2.40 + 0.20 2.10 + 0.30 2.60 + 0.40
Cu2(ASA)4 10 mg/kg 2.10+ 0.10 2.60+ 0.40 2.50+ 0.20 2.20+ 0.30
50 mg/kg 2.50 + 0.30 2.80 + 0.50 2.30 + 0.10 2.40 +- 0.20
Table 6. Copper concentration(x+S.E.M, n=20) in feces for non-treated
and copper aspirinate-treated rats at the end of the third month
Group Dose Cu(/g/g wet mass)
control 38.00 + 3.00
Cu2(ASA)4 10 mg/kg 184.00 + 5.00
50 mg/kg 496.00 +_ 10.00
The projected human dose of copper aspirinate is 2 mg/kg daily with a decrease
to some maintenance dose with remission [7]. The 50 mg/kg dose used in these
studies is 25 times the projected therapeutic dose but does not cause
accumulation of copper. We conclude that copper aspirinate is safe for clinical
use.
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